Simultaneous quantification of linezolid, rifampicin, levofloxacin, and moxifloxacin in human plasma using high-performance liquid chromatography with UV

Therapeutic Drug Monitoring

Volumn 31, Issue 1, 2009, Pages 104-109

  Baietto, Lorena ^a,b   D'Avolio, Antonio ^a   De Rosa, Francesco Giuseppe ^a   Garazzino, Silvia ^a   Patanella, Samantha ^a   Siccardi, Marco ^a   Sciandra, Mauro ^a   Di Perri, Giovanni ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b NONE   (Italy)

Author keywords

Fluoroquinolones; HPLC UY; Linezolid; Rifampicin; Therapeutic drug monitoring

Indexed keywords

ABACAVIR; ACETYLSALICYLIC ACID; AMOXICILLIN; AMPICILLIN; AMPRENAVIR; ATORVASTATIN; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; DIDANOSINE; ENALAPRIL MALEATE; ETHAMBUTOL; FUROSEMIDE; INDINAVIR; ISONIAZID; LAMIVUDINE; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; NELFINAVIR; PIPERACILLIN; PYRAZINAMIDE; RIFAMPICIN; SAQUINAVIR; STAVUDINE; SULFAMETHOXAZOLE; TEICOPLANIN; TRIMETHOPRIM; UNINDEXED DRUG; ZIDOVUDINE;

ACCURACY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; ULTRAVIOLET RADIATION;

ACETAMIDES; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTITUBERCULAR; AZA COMPOUNDS; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; OFLOXACIN; OXAZOLIDINONES; QUALITY CONTROL; QUINOLINES; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; RIFAMPIN; SOLUTIONS; SOLVENTS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 60449096076     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31819476fa     Document Type: Article

References (55)

1. Clemett D, Markham A. Linezolid. Drugs. 2000;59:815-827.
2. Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet. 2001;358: 1975-1982.
3. Dresser LD, Rybak MJ. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy. 1998;18:456-462.
4. Perry CM, Jarvis B. Linezolid - a review of its use in the management of serious Gram-positive infections. Drugs. 2001;61:525-551.
5. Ross JE, Pritsche TR, Sader HS, et al. Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox® Annual Appraisal of Potency and Spectrum Study. Int J Antimicrob Agents. 2007;29: 295-301.
6. Product information. Zyvox (linezolid) Pharmacia. In: Thomas J, ed. Australian prescription products guide. 34th ed. Melbourne, Australia: Australian Pharmaceutical Publishing Company, 2005:3896-3900.
7. Kaka AS, Rueda AM, Shelburne SA, et al. Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2006;58:680-683.
8. Shi R, Itagaki N, Sugawara I. Overview of antituberculosis (TB) drugs and their resistance mechanisms. Mini Rev Med Chem. 2007;7:1177-1185.
9. Rodriguez JC, Cebrian L, Lopez M, et al. Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis. J Antimicrob Chemother. 2004;53:441-444.
10. Tomioka H. Current status of some antituberculosis drugs and the development of new antituberculosis agents with special reference to their in vitro and in vivo antimicrobial activities. Curr Pharm Des. 2006;12: 4047-4070.
11. Barry PJ, O'Connor TM. Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14:2000-2008.
12. Molicotti P, Ortu S, Bua A, et al. In vitro efficacy of linezolid on clinical strains of Mycobacterium tuberculosis and other mycobacteria. New Microbiol. 2006;29:275-280.
13. WHO. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. 2006 (WHO HTM TB2006 361).
14. Tato M, de la Pedrosa EGG, Canton R, et al. In vitro activity of linezolid against Mycobacterium tuberculosis complex, including multidrug-resistant Mycobacterium bovis isolates. Int J Antimicrob Agents. 2006; 28:75-78.
15. Dailey CF, Pagano PJ, Buchanan LY et al. Efficacy of linezolid plus rifampin in an experimental model of methicillin-susceptible Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 2003;47:2655-2658.
16. Sahuquillo Arce JM, Colombo Gainza E, Gil Brusola A, et al. In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus. Rev Esp Quimioter. 2006;19:252.
17. Gebhart BC, Barker BC, Markewitz BA. Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin. Pharmacotherapy. 2007;27:476-479.
18. Borner K, Borner E, Lode H. Determination of linezolid in human serum and urine by high-performance liquid chromatography. Int J Antimicrob Agents. 2001;18:253-258.
19. Boak LM, Li J, Nation RL, et al. High-performance liquid Chromatographic method for simple and rapid determination of linezolid in human plasma. Biomed Chromatogr. 2006;20:782-786.
20. Buerger C, Joukhadar C, Muller M, et al. Development of a liquid chromatography method for the determination of linezolid and its application to in vitro and human microdialysis samples. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;796:155-164.
21. Tobin CM, Sunderland J, White LO, et al. A simple, isocratic high-performance liquid chromatography assay for linezolid in human serum. J Antimicrob Chemother. 2001;48:605-608.
22. Toutain J, Boselli E, Djabarouti S, et al. Determination of linezolid in plasma and bronchoalveolar lavage by high-performance liquid chromatography with ultraviolet detection using a fully automated extraction method. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;813: 145-150.
23. Liang HR, Kays MB, Sowinski KM. Separation of levofloxacin, ciprofloxacin, gatifloxacin, moxifloxacin, trovafloxacin and cinoxacin by high-performance liquid chromatography: application to levofloxacin determination in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;772:53-63.
24. Nguyen HA, Grellet J, Ba BB, et al. Simultaneous determination of levofloxacin, gatifloxacin and moxifloxacin in serum by liquid chroma-tography with column switching. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;810:77-83.
25. Djabarouti S, Boselli E, Allaouchiche B, et al. Determination of levofloxacin in plasma, bronchoalveolar lavage and bone tissues by high-performance liquid chromatography with ultraviolet detection using a fully automated extraction method. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;799:165-172.
26. Zhou ZL, Yang M, Yu XY, et al. A rapid and simple high-performance liquid chromatography method for the determination of human plasma levofloxacin concentration and its application to bioequivalence studies. Biomed Chromatogr. 2007;21:1045-1051.
27. Laban-Djurdjevic A, Jelikic-Stankov M, Djurdjevic P. Optimization and validation of the direct HPLC method for the determination of moxifloxacin n plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;844:104-111.
28. Boffito M, Tija J, Reynolds HE, et al. Simultaneous determination of rifampicin and efavirenz in plasma. Ther Drug Monit. 2002;24:670-674.
29. Hartkoom RC, Khoo S, Back DJ, et al. A rapid and sensitive HPLC-MS method for the detection of plasma and cellular rifampicin. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;857:76-82.
30. Allanson AL, Cotton MM, Tettey JNA, et al. Determination of rifampicin in human plasma and blood spots by high performance liquid chromatography with UV detection: a potential method for therapeutic drug monitoring. J Pharm Biomed Anal. 2007;44:963-969.
31. Lau YY, Hanson GD, Carel BJ. Determination of rifampin in human plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B, Biomed Appl. 1996;676:147-152.
32. Guidance for Industry: Bioanalytical Method Validation. Available at: http://fda.gov/cder/guidance/4252fnl.pdf. Accessed September 20, 2007.
33. Begg EJ, Barclay ML, Kirkpatrick CMJ. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol. 2001;52:35S-43S.
34. Begg EJ. Individualising drug and dose - the clinical pharmacologist's calling or curse? Clin Exp Pharmacol Physiol. 2004;31:A215.
35. Deryke CA, Du XL, Nicolau DP. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae. J Antimicrob Chemother. 2006;58:601-609.
36. Roberts JA, Lipman J. Antibacterial dosing in intensive care - pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet. 2006;45:755-773.
37. Stalker DJ, Jungbluth GL, Hopkins NK, et al. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother. 2003;51:1239-1246.
38. Andes D, Craig WA. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob Agents Chemother. 2002;46:1665-1670.
39. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1-10.
40. Drusano GL, Johnson DE, Rosen M, et al. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother. 1993;37:483-490.
41. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill-patients. Antimicrob Agents Chemother. 1993;37:1073-1081.
42. Ray J, Gardiner I, Marriott D. Managing antituberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid. Intern Med J. 2003;33:229-234.
43. Nijland HMJ, Ruslami R, Suroto AJ, et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis. 2007;45:1001-1007.
44. Weiner M, Burman W, Luo CC, et al. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother. 2007;51:2861-2866.
45. Whitehouse T, Cepeda JA, Shulman R, et al. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. J Antimicrob Chemother. 2005;55:333-340.
46. Stein GE, Schooley S, Peloquin CA, et al. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob Chemother. 2007;60:819-823.
47. Myrianthefs P, Markantonis SL, Vlachos K, et al. Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients. Antimicrob Agents Chemother. 2006;50:3971-3976.
48. Dehghanyar P, Burger C, Zeitlinger M, et al. Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses. Antimicrob Agents Chemother. 2005;49:2367-2371.
49. Peloquin CA, Hadad DJ, Molino LPD, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2008;52: 852-857.
50. Esposito S, Noviello S, D'Errico G, et al. Concentration of moxifloxacin in plasma and tonsillar tissue after multiple administration in adult patients. J Antimicrob Chemother. 2006;57:789-792.
51. Sullivan JT, Lettieri JT, Liu P, et al. The influence of age and gender on the pharmacokinetics of moxifloxacin. Clin Pharmacokinet. 2001;40: 11-18.
52. Stass H, Kubitza D, Schuhly U. Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration. Clin Pharmacokinet. 2001;40:1-9.
53. Ruslami R, Nijland HMJ, Lisjahbana BA, et al. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother. 2007;51: 2546-2558.
54. van Crevel R, Alisjahbana B, de Lange WCM, et al. Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia. Int J Tuberc Lung Dis. 2002;6:497-502.
55. Ziglam HM, Baldwin DR, Daniels I, et al. Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother. 2002;50:1011-1015.